AstraZeneca Covid Vaccine Backed by EU Regulators

The European Medicines Agency (EMA) has emphasized the benefits of the AstraZeneca vaccine despite concerns about blood clots. This message contradicts some European governments' hesitations, leading to reputational damage for AstraZeneca. The uptake of AstraZeneca is lower compared to other vaccines like Pfizer, posing a problem amid high infection rates. The situation is complicated by political and communication challenges, with public trust being a significant issue.

What is the main concern that some European governments have about the AstraZeneca vaccine?

• Its effectiveness against new variants

• Potential blood clots

• High cost

• Storage requirements

Which vaccine is primarily used in Europe, according to the transcript?

• Pfizer-BioNTech

• Sputnik V

• Moderna

• Johnson & Johnson

What action did Spain, Germany, Italy, and France take regarding the AstraZeneca vaccine?

• Reduced its price

• Approved it for children

• Increased its distribution

• Suspended its use

What is a major issue affecting the public's perception of the AstraZeneca vaccine?

• Lack of availability

• Complex administration process

• Political communication problems

• High cost

How many times in a week did the regulator affirm the safety of the AstraZeneca vaccine?

• Twice

• Once

• Four times

• Three times